The question at hand is whether taking aspirin can diminish the therapeutic benefits of Vascepa, a prescription medication used to reduce triglyceride levels in adult patients with severe (500 mg/dL or higher) hypertriglyceridemia [1]. According to the drug's manufacturer, Amarin Pharma Inc., Vascepa contains the active ingredient icosapent ethyl [1].

There is limited research directly addressing the interaction between aspirin and Vascepa. However, a study published in the American Journal of Cardiology in 2013 investigated the effects of adding aspirin to another triglyceride-lowering drug, omega-3-acid ethyl esters (Lovaza) [2]. The researchers found that aspirin did not interfere with the triglyceride-lowering effects of omega-3-acid ethyl esters [2].

While this study does not directly address Vascepa, it does suggest that aspirin may not diminish the therapeutic benefits of triglyceride-lowering drugs in general. It is important to note that individual patient responses may vary, and it is always best to consult with a healthcare provider before adding or changing medications.

In summary, there is limited evidence on the interaction between aspirin and Vascepa, but a study on a related drug suggests that aspirin may not interfere with triglyceride-lowering benefits [2]. Consult with a healthcare provider for personalized advice.

Sources:
[1] DrugPatentWatch.com. (n.d.). Vascepa. Retrieved from https://www.drugpatentwatch.com/drugs/vascepa
[2] Bays, H. E., Maki, K. C., Doyle, R. T., Champagne, J., & Stein, E. A. (2013). A randomized, double-blind, placebo-controlled trial of 4 g/day of omega-3 acid ethyl esters and low-dose aspirin in patients with hypertriglyceridemia. American Journal of Cardiology, 111(5), 631-637. doi: 10.1016/j.amjcard.2012.11.034